GILEAD SCIENCES, INC. Federal Income Tax Expense (Benefit), Continuing Operations
GILEAD SCIENCES, INC. (GILD) reported Federal Income Tax Expense (Benefit), Continuing Operations of $1.24 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-02-24
- GILEAD SCIENCES, INC. federal income tax expense (benefit), continuing operations for fiscal 2025 was $1.24B.
- GILEAD SCIENCES, INC. federal income tax expense (benefit), continuing operations for fiscal 2024 was -$67.00M, a 110.23% decline from fiscal 2023.
- GILEAD SCIENCES, INC. federal income tax expense (benefit), continuing operations for fiscal 2023 was $655.00M, a 36.84% decline from fiscal 2022.
- GILEAD SCIENCES, INC. federal income tax expense (benefit), continuing operations for fiscal 2022 was $1.04B, a 32.04% decline from fiscal 2021.
| Period end | Federal Income Tax Expense (Benefit), Continuing Operations 12 month | Federal Income Tax Expense (Benefit), Continuing Operations 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.24B 10-K · filed 2026-02-24 | |
| 2024-12-31 | -$67.00M 10-K · filed 2026-02-24 | |
| 2023-12-31 | $655.00M 10-K · filed 2026-02-24 | |
| 2022-12-31 | $1.04B 10-K · filed 2025-02-28 | |
| 2021-12-31 | $1.53B 10-K · filed 2024-02-23 | |
| 2020-12-31 | $1.29B 10-K · filed 2023-02-22 | |
| 2019-12-31 | $803.00M 10-K · filed 2022-02-23 | |
| 2018-12-31 | $2.04B 10-K · filed 2021-02-25 | |
| 2017-12-31 | $8.69B 10-K · filed 2020-02-25 | |
| 2016-12-31 | $3.27B 10-K · filed 2019-02-26 | |
| 2015-12-31 | $3.25B 10-K · filed 2018-02-27 | |
| 2014-12-31 | $2.62B 10-K · filed 2017-02-27 | |
| 2013-12-31 | $1.08B 10-K · filed 2016-02-24 | $1.08B 10-K · filed 2014-02-25 |
| 2012-12-31 | $978.00M 10-K · filed 2015-02-25 | $977.68M 10-K · filed 2013-02-27 |
| 2011-12-31 | $772.80M 10-K · filed 2014-02-25 | |
| 2010-12-31 | $822.97M 10-K · filed 2013-02-27 | |
| 2009-12-31 | $672.17M 10-K · filed 2012-02-23 | |
| 2008-12-31 | $591.17M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |